Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mirabegron vs Anticholinergics in SCI Neurogenic Bladder
NCT03612401Phase 1Completed
- Sponsor
- UT Health San Antonio
- Start
- Dec 2018
- Primary completion
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of mirabegron in neurogenic bladder, sponsored by UT Health San Antonio. Primary endpoint: Logical Memory I (Immediate) at 26 weeks. Started Dec 2018; status: completed.
02
Drugs
mirabegron
03
Conditions
neurogenic bladder
Beyond the preview
Go deeper on NCT03612401.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03612401.